Biotechnology Following the recent spate of approvals in both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), the treatment landscape is becoming increasingly difficult to navigate for both physicians and patients, highlighting the need for better education, access, and infrastructure to support physicians’ and patients’ choices of the optimal therapies. 15 November 2018